FDA Focuses ANDA Reviews on Basis of Risk
This article was originally published in The Gold Sheet
A risk-ranking pilot went so well that FDA’s Office of Generic Drugs has swiftly expanded use of the technique to help focus the attention of reviewers, swamped by GDUFA deadline-studded, QbD-packed ANDAs, on the quality issues that will have the greatest impact on patient safety.
You may also be interested in...
A dashboard tool US FDA is developing promises to liberate key information from the agency’s trove of CMC review documents, enabling greater consistency among reviews and a greater emphasis on the manufacturing issues that pose the greatest risks.
Crude heparin supplier Yibin Lihao headlines list of facilities in 12 countries added to the US FDA’s drug GMP import alert.
The Quality Lowdown: Warning Letters, Nitrosamine Recalls And Sen. Warren's Generics Manufacturing Plan
Manufacturers warned on quality basics like testing and keeping records and reminded about nitrosamine deadlines; Senator Elizabeth Warren clarifies government drug manufacturing idea.